Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 16, Issue 11, 2006, Pages 745-748

  Cripe, Linda H ^a   Barber, Brent J ^b   Spicer, Robert L ^a   Wong, Brenda L ^a   Weidner, Norbert ^a   Benson, D Woodrow ^a   Markham, Larry W ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Dobutamine; Duchenne muscular dystrophy; Inotropes; Milrinone

Indexed keywords

DOBUTAMINE; MILRINONE;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE CLASSIFICATION; DUCHENNE MUSCULAR DYSTROPHY; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; DISEASE PROGRESSION; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOME INFUSION THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MILRINONE; MUSCULAR DYSTROPHY, DUCHENNE; PALLIATIVE CARE; QUALITY OF LIFE; TIME FACTORS;

EID: 33750465212     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.07.021     Document Type: Article

References (12)

1. Rando T. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24 12 (2001) 1575-1594
2. Cohn R.D., and Campbell K.P. Molecular basis of muscular dystrophies. Muscle Nerve 23 10 (2000) 1456-1471
3. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
4. Heart Failure Society Of A. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12(1):e1-2.
5. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 21 2 (2002) 189-203
6. Hampton J.R., van Veldhuisen D.J., Kleber F.X., Cowley A.J., Ardia A., Block P., et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 349 9057 (1997) 971-977
7. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 21 (1991) 1468-1475
8. Lubsen J., Just H., Hjalmarsson A.C., La Framboise D., Remme W.J., Heinrich-Nols J., et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 76 3 (1996) 223-231
9. Cohn J.N., Goldstein S.O., Greenberg B.H., Lorell B.H., Bourge R.C., Jaski B.E., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339 25 (1998) 1810-1816
10. Matsumura T., Saito T., Miyai I., Nozaki S., and Kang J. Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure. Rinsho Shinkeigaku 39 6 (1999) 643-648
11. Cusick D.A., Pfeifer P.B., and Quigg R.J. Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. Am J Cardiol 82 9 (1998) 1060-1065
12. Felker G.M., Benza R.L., Chandler A.B., Leimberger J.D., Cuffe M.S., Califf R.M., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 6 (2003) 997-1003